ArticleJournal of general and family medicine2025
A case of idiosyncratic drug-induced agranulocytosis because of sulbactam/ampicillin.
Article in Journal of general and family medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A case of idiosyncratic drug-induced agranulocytosis because of sulbactam/ampicillin.Journal of general and family medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiosyncratic drug-induced agranulocytosis is a rare but life-threatening condition that requires immediate medical intervention. Although sulbactam/ampicillin (SBT/ABPC) is a widely used antibiotic, no prior case reports of its associated agranulocytosis were identified in our narrative literature review. We present a case of an 85-year-old man who developed agranulocytosis following SBT/ABPC treatment for pressure ulcer infection and aspiration pneumonia, accompanied by a narrative literature review. Awareness of this condition, prompt discontinuation of the suspected agent, and close monitoring of total white blood cell counts are essential for early detection and management of this life-threatening complication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.